SpyGlass Pharma, Inc. Common Stock (SGP) — Stock Valuation & Research

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in…

SGP key statistics

Price$34.49
Market cap$1.15B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range17.06-34.83
Beta-0.89

Explore SGP's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.